ReviewActa neurochirurgica2022
The WHO 2021 Classification of Central Nervous System tumours: a practical update on what neurosurgeons need to know-a minireview.
Review in Acta neurochirurgica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 168 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
168 citing papers in PubMed, 2 syntheses or guidelines pooled it, 258 citations in OpenAlex.
- Pre-operative MRI-Based Radiomics for Predicting Telomerase Reverse Transcriptase Promoter Mutation Status in Glioma Patients: A Systematic Review and Meta-analysis.Neurosurgical review · 2026Pooled it
- Air Pollution and Brain Tumors in Children. A Systematic Review.Current environmental health reports · 2026Pooled it
- Intracranial solitary fibrous tumor with multiloculated cystic change: A case report.Radiology case reports · 2026Article
- The potential role of miR-34a and miR-34c in the regulation of pediatric high-grade glioma 4 aggressiveness.Pediatric research · 2026Article
- Optimizing MRI sequence selection for glioma classification: a radiomics-based analysis of WHO CNS grade, final pathological diagnosis, and IDH status.La Radiologia medica · 2026Article
- Malignant transformation of lower-grade glioma: contrast enhancement, extent of resection, and the natural history under interval-censored analysis.Journal of neuro-oncology · 2026Article
- Diagnostic Pitfalls of Oligodendroglioma-like Morphology: Integrated Reappraisal of 23 Non-Oligodendroglial Central Nervous System Tumors.Diagnostics (Basel, Switzerland) · 2026Article
- Immunotherapy for Glioma: A compartmental framework for resistance and rational combination design.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Review
- Paediatric sellar mature teratoma with isolated growth hormone deficiency - A case-based review.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026Review
- Association Between Temozolomide Resistance and Long Non-Coding RNA Expression Profiles in Glioblastoma Cell Lines.Pharmaceuticals (Basel, Switzerland) · 2026Article
- An Algorithm at the Table at Multidisciplinary Diagnostic Meetings: A Dramaturgical Analysis.Sociology of health & illness · 2026Article
- Supramaximal resection in gliomas: a narrative review of surgical techniques, clinical outcomes, and ethical considerations.Annals of medicine and surgery (2012) · 2026Review
- Invasive sellar extraventricular neurocytoma: illustrative case.Journal of neurosurgery. Case lessons · 2026Article
- Advances and challenges in glioblastoma immunotherapy: a meta-analysis of immune checkpoint inhibitors.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Segmentation-Free Preoperative 3D MRI Classification of Low-Grade Versus High-Grade Glioma Using Task-Oriented Neural Architecture Search.Journal of imaging · 2026Article
- Glioblastoma treatment patterns and outcomes over 18 years in an Irish cancer centre.Irish journal of medical science · 2026Article
- MRI Deep Learning for Differentiating Glioblastoma, IDH Wild-type from Central Nervous System Diffuse Large B-cell Lymphoma.Cancer research communications · 2026Article
- Evolving Landscape of Glioblastoma Research: Integrating Therapeutic Advances and Diagnostic Frontiers.Brain sciences · 2026Review
- Molecular signature of SETD2 and m6A modifiers in the pathogenesis of different grades of adult-type diffuse gliomas.Molecular biology reports · 2026Article
- Article
108 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe World Health Organization (WHO) Classification of Tumours, also known as WHO Blue Books, represents an international standardised tool in the diagnostic work-up of tumours. This classification system is under continuous revision, and progress in the molecular classification of tumours in the central nervous system (CNS) enforced an update of the WHO 2016 classification, and the fifth edition, WHO CNS5, was published in 2021. The aim of this minireview is to highlight important changes in this new edition relevant for the practicing neurosurgeon.
methodsThe sixth volume of the fifth edition of the WHO Blue Books of CNS tumours and related papers formed the basis for this minireview.
resultsMajor changes encompass standardisation of tumour grading and nomenclature as well as increased incorporation of molecular markers in the classification of CNS tumours.
conclusionAdvances in molecular genetics have resulted in more accurate diagnosis and prognosis of CNS tumours, and this minireview summarises important changes implemented in the last edition of WHO classification of CNS tumours important for the practicing neurosurgeon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.